eligibility_summary
Eligibility: Adults ≥18, ECOG 0–1, ≥12‑wk survival, unresectable/metastatic solid tumors (Stage Ib after standard therapy or Stage II treatment‑naive), measurable lesion, adequate organs, tumor tissue, contraception. Exclude: active CNS mets, prior topo I ADCs (PD‑1/PD‑L1 in Stage II), recent therapy/RT/immunosuppression/surgery/infection, severe irAEs, autoimmune disease or ILD, active HBV/HCV/TB, cardiac/effusions, pregnancy, live vaccine, psychiatric/substance abuse, PI judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06417554 evaluates SHR-A2102 alone or with adebrelimab in adults with advanced solid tumors. Drugs/interventions and mechanisms: • SHR-A2102: antibody–drug conjugate (ADC). Binds a tumor-associated antigen (antigen not specified in registry), is internalized, and releases a topoisomerase I inhibitor payload, causing DNA damage during replication and tumor cell death, potential bystander effect. • Adebrelimab: anti–PD-L1 monoclonal antibody (immune checkpoint inhibitor) that blocks PD-L1/PD-1 interaction to restore T-cell activation and antitumor immunity. Cells/pathways targeted: • Antigen-positive tumor cells (via the ADC), DNA replication/topoisomerase I pathway leading to cytotoxicity. • PD-1/PD-L1 immune checkpoint on tumor and immune cells (T cells, APCs), enhancing cytotoxic T-cell responses. Design: Phase Ib/II, parallel arms (SHR-A2102 vs SHR-A2102 + adebrelimab), China.